Intelligence / Healthtech / New Clinical Trials / AVEO Pharmaceuticals, Inc.
Clinicaltrial registered22 Oct 2026
AVEO Pharmaceuticals, Inc.
22 Oct 2026: Trial registered · Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 22 Oct 2026
- Title
- Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Phase
- Phase 2, Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07888075
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at AVEO Pharmaceuticals, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.